Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Work In Process (2021 - 2023)

Historic Work In Process for Kiniksa Pharmaceuticals International (KNSA) over the last 3 years, with Q4 2023 value amounting to $18.3 million.

  • Kiniksa Pharmaceuticals International's Work In Process rose 18925.86% to $18.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $18.3 million, marking a year-over-year increase of 18925.86%. This contributed to the annual value of $18.3 million for FY2023, which is 18925.86% up from last year.
  • Kiniksa Pharmaceuticals International's Work In Process amounted to $18.3 million in Q4 2023, which was up 18925.86% from $13.4 million recorded in Q3 2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Work In Process ranged from a high of $18.3 million in Q4 2023 and a low of $148000.0 during Q1 2022
  • Its 3-year average for Work In Process is $8.3 million, with a median of $6.5 million in 2022.
  • Data for Kiniksa Pharmaceuticals International's Work In Process shows a peak YoY increase of 903310.81% (in 2023) and a maximum YoY decrease of 18925.86% (in 2023) over the last 5 years.
  • Quarter analysis of 3 years shows Kiniksa Pharmaceuticals International's Work In Process stood at $4.2 million in 2021, then soared by 50.9% to $6.3 million in 2022, then surged by 189.26% to $18.3 million in 2023.
  • Its Work In Process stands at $18.3 million for Q4 2023, versus $13.4 million for Q3 2023 and $6.6 million for Q2 2023.